Logo.png
BioRestorative Therapies Announces Closing of $23 Million Public Offering
November 09, 2021 14:20 ET | BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
Wereldhave_sRGB.png
Wereldhave commits to setting Science-Based Targets
March 13, 2020 03:29 ET | Wereldhave N.V.
Press release | Wereldhave commits to setting Science-Based TargetsWereldhave is pleased to announce it has committed itself to reduce carbon emissions to a level in line with what climate science...
ritter.jpg
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 09:15 ET | Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
bio-restorative-therapies-logo-final[1].png
BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program
December 12, 2019 09:45 ET | BioRestorative Therapies, Inc.
MELVILLE, N.Y., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...
bio-restorative-therapies-logo-final[1].png
BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program
October 23, 2019 09:45 ET | BioRestorative Therapies, Inc.
MELVILLE, N.Y., Oct. 23, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the...
ritter.jpg
Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives
October 07, 2019 09:00 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
ritter.jpg
Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
December 04, 2018 08:30 ET | Ritter Pharmaceuticals, Inc.
Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...
ritter.jpg
Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
November 06, 2018 07:00 ET | Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial  for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...
ritter.jpg
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance
May 22, 2018 08:30 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split
March 22, 2018 11:35 ET | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that...